Live Breaking News & Updates on Company On Twitter At Milestonepharma

Stay updated with breaking news from Company on twitter at milestonepharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21

/PRNewswire/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative. ....

United States , David Pitts , Joseph Oliveto , Bruce Stambler , Milestone Pharmaceuticals Inc , Company On Twitter At Milestonepharma , Piedmont Heart Institute , American College Of Cardiology , Exchange Commission , Milestone Pharmaceuticals , Significant Improvements , Associated Symptoms , Patients Treated , Etripamil Compared , American College , Annual Scientific Session , Analysis Of Clinical Outcomes In The , Chief Executive Officer , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் குழிகள் , ஜோசப் ஆலிவேடோ , மைல்கல் மருந்துகள் இன்க் , பீட்‌மாஂட் இதயம் நிறுவனம் , அமெரிக்கன் கல்லூரி ஆஃப் இருதயவியல் , பரிமாற்றம் தரகு ,

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China

Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China
- Ji Xing Pharmaceuticals to develop and commercialize etripamil for patients with PSVT in Greater China -
- Milestone to receive a $15 million upfront cash payment and a $5 million equity investment by RTW Investments, LP -
News provided by
Share this article
Share this article
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced an exclusive license and collaboration agreement with Ji Xing Pharmaceuticals (Ji Xing) to develop and, if approved, commercialize the investigational drug etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) and additional cardiovascular conditions in Greater China. J ....

Ji Xing , United States , Peter Fong , David Pitts , Joseph Oliveto , Milestone Pharmaceuticals Inc , Company On Twitter At Milestonepharma , Ji Xing Pharmaceuticals , Prnewswire Milestone Pharmaceuticals Inc , Exchange Commission , Head Of Company Creation , Milestone Pharmaceuticals , Chief Executive Officer , Company Creation , New York Based , Private Securities Litigation Reform Act , ஜி க்ஷிங் , ஒன்றுபட்டது மாநிலங்களில் , பீட்டர் பொங் , டேவிட் குழிகள் , ஜோசப் ஆலிவேடோ , மைல்கல் மருந்துகள் இன்க் , ஜி க்ஷிங் மருந்துகள் , பரிமாற்றம் தரகு , தலை ஆஃப் நிறுவனம் படைப்பு , மைல்கல் மருந்துகள் ,

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update

Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
News provided by
Share this article
Share this article
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update.
We continue to work closely with our existing clinical trial sites, as well as add new sites, to address the impact that the COVID-19 pandemic has had on patient enrollment in the pivotal Phase 3 RAPID trial of etripamil in patients with PSVT. While we are encouraged by recent improvements in enrollment rates, we now expect to report topline data from the RAPID trial in the second half of 2022, said Joseph Oliveto, President ....

United States , Ji Xing , David Pitts , Joseph Oliveto , Bruce Stambler , Montreal Heart Institute , Company On Twitter At Milestonepharma , Prnewswire Milestone Pharmaceuticals Inc , Ji Xing Pharmaceuticals To , Centers For Disease , Milestone Pharmaceuticals Inc , American College Of Cardiology , Piedmont Heart Institute , Drug Administration , Ji Xing Pharmaceuticals , Company Expects To Report Topline Data , Exchange Commission , Milestone Pharmaceuticals , Chief Executive Officer , Exclusive License Agreement , Commercialize Etripamil , Report Topline Data , Pivotal Phase , New Drug Application , Label Safety Study Amended , Include Repeat Dose ,

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences
News provided by
Share this article
Share this article
MONTREAL and CHARLOTTE, N.C., Feb. 25, 2021 /PRNewswire/ Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that Joseph Oliveto, President and Chief Executive Officer, will present at the following investor conferences:
The Cowen 41
st Annual Health Care Conference s panel on Cardiovascular Disease and Hospital Products on Thursday, March 4, 2021 at 1:30 p.m. Eastern Time.
The H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 on demand beginning at 7:00 a.m. Eastern Time. ....

United States , David Pitts , Joseph Oliveto , Milestone Pharmaceuticals Inc , Company On Twitter At Milestonepharma , Milestone Pharmaceuticals , Healthcare Conference , Prnewswire Milestone Pharmaceuticals Inc , Chief Executive Officer , Annual Healthcare Conference , Cardiovascular Disease , Hospital Products , Global Life Sciences Conference , ஒன்றுபட்டது மாநிலங்களில் , டேவிட் குழிகள் , ஜோசப் ஆலிவேடோ , மைல்கல் மருந்துகள் இன்க் , மைல்கல் மருந்துகள் , சுகாதாரம் மாநாடு , தலைமை நிர்வாகி அதிகாரி , ஆண்டு சுகாதாரம் மாநாடு , இருதய நோய் , மருத்துவமனை ப்ராடக்ட்ஸ் , உலகளாவிய வாழ்க்கை அறிவியல் மாநாடு ,